International WELL Building Institute Opens Enrollment for WELL Health-Safety Rating In Response to COVID-19 With Significant Early Adoption
The International WELL Building Institute (IWBI) announced that enrollment has opened today for the WELL Health-Safety Rating for Facility Operations and Management, with more than 100 organizations and real estate portfolios across the globe already enrolled. Organizations across a wide range of industries and geographic locations have responded swiftly to implement the program’s science-backed guidance as they seek to instill confidence and trust among their staff, stakeholders and the broader community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005768/en/
The WELL Health-Safety Rating is an evidence-based, third-party verified rating for all new and existing building and space types focused on operational policies, maintenance protocols, emergency plans and stakeholder engagement strategies to help organizations prepare their spaces for re-entry in a post COVID-19 environment.
Adapted from features in the WELL Building Standard (WELL) that focus on facilities, maintenance and operations, the WELL Health-Safety Rating is designed to guide and empower the actions of large and small businesses alike in taking the necessary steps to prioritize the health and safety of their staff, visitors and stakeholders. It also serves as an annual process that supports efforts to promote the long-term health and safety of people.
“We’re all eager to get back to our workplaces, back to school, back to traveling, dining, and cheering on our favorite teams and performers,” said IWBI Chairman and CEO Rick Fedrizzi. “As organizations across the globe respond to the COVID-19 crisis through changes in policies and protocols, the WELL Health-Safety Rating delivers the evidence-based health strategies required to help them safely reopen with the confidence and integrity provided by third-party verification.”
Created by IWBI, the WELL Health-Safety Rating is informed by guidance developed by the World Health Organization (WHO), U.S. Centers for Disease Control and Prevention (CDC), global disease control and prevention centers and emergency management agencies, recognized standard-making bodies, such as ASTM International and ASHRAE, and leading academic and research institutions. IWBI has leveraged insights from its Task Force on COVID-19, established at the outset of the pandemic to help business and building leaders integrate actionable insights and proven strategies in the fight against COVID-19 and other respiratory infections.
“This moment has highlighted the critical role that buildings, and those that own and operate them, can play in supporting people’s health, safety and well-being,” said IWBI President Rachel Gutter. “This new rating aims to meet the urgent need to deliver high health and safety standards in all of the spaces we occupy. While longer term design strategies are important in reducing the risks of infectious disease spread, this rating focuses on strategies that can be implemented immediately to address acute threats, using our buildings and spaces as a first line of defense in the fight against COVID-19.”
Demonstrating thought leadership and commitment to the health and safety of their stakeholder communities, the following leading organizations are among the first that have enrolled to achieve the WELL Health-Safety Rating:
|
ACCIONA SA |
|
Adventist Health |
|
Aedifica |
|
Alpin Limited (Masdar City) |
|
American Savings Bank |
|
Bartra Capital Property |
|
CAMCO Management Co. |
|
Carrier |
|
Catalyst Partners |
|
CBD Z03 |
|
CBRE Barcelona |
|
CBRE Madrid |
|
China Overseas Office Capital |
|
Cleveland Clinic Courts / Cleveland Cavaliers |
|
Climate Change Arena |
|
Community Investment Strategies, Inc |
|
CR Land |
|
Deerns |
|
Delos China |
|
Delos Living LLC |
|
Delta Electronics, Inc. |
|
Denholtz Properties |
|
Department of Earth System Science, Tsinghua University |
|
Empire State Realty Trust |
|
EMSI |
|
GFP Real Estate |
|
Ghelamco Poland Sp. z o.o. |
|
Glenstar |
|
GuocoLand China Ltd. |
|
HBMSU |
|
Heitman |
|
Herman Miller Group |
|
Hornets Sports & Entertainment - Spectrum Center |
|
HRO |
|
Infancix Co., Ltd |
|
International Commerce Centre |
|
International WELL Building Institute PBC |
|
Ivanhoé Cambridge |
|
Jiahui Health |
|
JLL |
|
Karisma Hotels and Resorts |
|
Kilroy Realty Corporation |
|
Kimball |
|
Laguna |
|
Lendlease Australia Office Portfolios: Australian Prime Property Fund Commercial, Lendlease International Towers Sydney Trust and Lendlease One International Towers Sydney Trust |
|
Lincoln Property Company |
|
M Moser Associates |
|
Mace |
|
Maple Leaf Sports & Entertainment (MLSE), which encompasses the Toronto Maple Leafs (NHL), Toronto Raptors (NBA), Toronto FC (MLS), & Toronto Argonauts (CFL) |
|
Menarco Development Corporation |
|
Milliken & Company |
|
ML7 |
|
Montage International |
|
Moody Center
|
|
New Belmont Arena |
|
New York Yankees |
|
Oak View Group |
|
Out of the Box Ventures |
|
Overbury Morgan Lovell |
|
OVG Arena Alliance & Stadium Alliance |
|
OVG Facilities |
|
Pacers Sports & Entertainment: Bankers Life Fieldhouse (Indianapolis, Ind.) |
|
Pacers Sports & Entertainment: St. Vincent Center/Indiana Pacers Training Facility (Indianapolis, Ind.) |
|
Parmenter Realty Partners |
|
Phipps Conservatory and Botanical Gardens |
|
RMZ Corp |
|
Rocket Mortgage FieldHouse / Cleveland Cavaliers & Cleveland Monsters |
|
Royal Albert Hall |
|
Rubrik India Pvt Ltd |
|
Savanna |
|
Serpentini Auto Group |
|
Shanghai Landleaf Architecture Technology Co. Ltd |
|
ShouGang Group |
|
Sino-Ocean |
|
Space Matrix Design Consultants Pvt. Ltd
|
|
TAIPEI 101 Tower |
|
Taiwan Architecture & Building Center |
|
Teknion |
|
The Florida Panthers and BB&T Center |
|
The Forestias |
|
The Related Group |
|
Thornton Tomasetti |
|
TITANIUM OFFICE SOLUTIONS MEXICO |
|
Uber Technologies, Inc. |
|
UltraStar Harrah’s Ak Chin Resort Maricopa, Az. |
|
United Center |
|
Webster Bank Arena |
|
Wells Fargo Center, Philadelphia, Pa. |
|
Wolfgang Puck Fine Dining Group |
|
Woonerf Inc. |
|
Yuexiu Commercial |
Upon achieving the designation, IWBI will issue the building or space a WELL Health-Safety seal.
The WELL Health-Safety Rating draws on principles established by IWBI’s WELL Building Standard, the premier standard for healthy real estate, which has surpassed 590 million square feet in registrations across 62 countries since inception. The WELL Building movement has been further amplified by over 12,000 WELL Accredited Professionals (APs) and registrants across the globe.
To learn more about the WELL Health-Safety Rating and to enroll, please visit www.wellcertified.com/health-safety.
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. IWBI is a participant of the United Nations Global Compact, the world’s largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here.
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Health-Safety Rating and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005768/en/
Contact information
Media:
Judith Webb
media@wellcertified.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
